288 related articles for article (PubMed ID: 35935987)
1. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques.
Styles TM; Gangadhara S; Reddy PBJ; Sahoo A; Shiferaw A; Welbourn S; Kozlowski PA; Derdeyn CA; Velu V; Amara RR
Front Immunol; 2022; 13():914969. PubMed ID: 35935987
[TBL] [Abstract][Full Text] [Related]
2. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
3. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
5. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
[TBL] [Abstract][Full Text] [Related]
6. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
7. Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge.
Malherbe DC; Vang L; Mendy J; Barnette PT; Spencer DA; Reed J; Kareko BW; Sather DN; Pandey S; Wibmer CK; Robins H; Fuller DH; Park B; Lakhashe SK; Wilson JM; Axthelm MK; Ruprecht RM; Moore PL; Sacha JB; Hessell AJ; Alexander J; Haigwood NL
Front Immunol; 2020; 11():626464. PubMed ID: 33658998
[TBL] [Abstract][Full Text] [Related]
8. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
9. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.
Kwa S; Lai L; Gangadhara S; Siddiqui M; Pillai VB; Labranche C; Yu T; Moss B; Montefiori DC; Robinson HL; Kozlowski PA; Amara RR
J Virol; 2014 Sep; 88(17):9579-89. PubMed ID: 24920805
[TBL] [Abstract][Full Text] [Related]
10. Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene
Chea LS; Wyatt LS; Gangadhara S; Moss B; Amara RR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541829
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Barouch DH; Tomaka FL; Wegmann F; Stieh DJ; Alter G; Robb ML; Michael NL; Peter L; Nkolola JP; Borducchi EN; Chandrashekar A; Jetton D; Stephenson KE; Li W; Korber B; Tomaras GD; Montefiori DC; Gray G; Frahm N; McElrath MJ; Baden L; Johnson J; Hutter J; Swann E; Karita E; Kibuuka H; Mpendo J; Garrett N; Mngadi K; Chinyenze K; Priddy F; Lazarus E; Laher F; Nitayapan S; Pitisuttithum P; Bart S; Campbell T; Feldman R; Lucksinger G; Borremans C; Callewaert K; Roten R; Sadoff J; Scheppler L; Weijtens M; Feddes-de Boer K; van Manen D; Vreugdenhil J; Zahn R; Lavreys L; Nijs S; Tolboom J; Hendriks J; Euler Z; Pau MG; Schuitemaker H
Lancet; 2018 Jul; 392(10143):232-243. PubMed ID: 30047376
[TBL] [Abstract][Full Text] [Related]
12. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
[TBL] [Abstract][Full Text] [Related]
13. A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques.
Sahoo A; Jones AT; Cheedarla N; Gangadhara S; Roy V; Styles TM; Shiferaw A; Walter KL; Williams LD; Shen X; Ozorowski G; Lee WH; Burton S; Yi L; Song X; Qin ZS; Derdeyn CA; Ward AB; Clements JD; Varadarajan R; Tomaras GD; Kozlowski PA; Alter G; Amara RR
Sci Immunol; 2022 Jul; 7(73):eabl4102. PubMed ID: 35867800
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.
Curtis AD; Saha PT; Dennis M; Berendam SJ; Ramasubramanian P; Cross KA; Alam SM; Ferrari G; Kozlowski PA; Fouda GG; Hudgens MG; Van Rompay KKA; Pollara J; Permar SR; De Paris K
mSphere; 2022 Feb; 7(1):e0083921. PubMed ID: 35196125
[TBL] [Abstract][Full Text] [Related]
15. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
Smith JM; Amara RR; Campbell D; Xu Y; Patel M; Sharma S; Butera ST; Ellenberger DL; Yi H; Chennareddi L; Herndon JG; Wyatt LS; Montefiori D; Moss B; McClure HM; Robinson HL
AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1335-47. PubMed ID: 15650426
[TBL] [Abstract][Full Text] [Related]
16. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
[TBL] [Abstract][Full Text] [Related]
17. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
18. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.
Lai L; Kwa SF; Kozlowski PA; Montefiori DC; Nolen TL; Hudgens MG; Johnson WE; Ferrari G; Hirsch VM; Felber BK; Pavlakis GN; Earl PL; Moss B; Amara RR; Robinson HL
Vaccine; 2012 Feb; 30(9):1737-45. PubMed ID: 22178526
[TBL] [Abstract][Full Text] [Related]
19. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
